Thursday, 14 December 2017

New trial alert: Ipatasertib in combination with Paclitaxel as a treatment for patients with PIK3CA/AKT1/PTEN-altered, locally advanced or metastatic, triple-negative breast cancer

A new clinical trial, being conducted at Sunnybrook Health Sciences Centre in Toronto, is seeking to evaluate the efficiency of ipatasertib + paclitaxel in patients with locally advanced or metastatic triple-negative breast cancer. The primary outcome of this investigation is progression-free survival, while secondary outcomes include health status, health-related quality of life, incidence and severity of adverse events, and changes in vital signs. This trial is currently in pending status, with an anticipated December 2017 start date.

To read more about this trial, click here.

1 comment:

  1. Paclitaxel, derived from the bark of the Pacific yew tree, has a broad antineoplastic spectrum used in cancer chemotherapy. It promotes and stabilizes tubulin polymerization, leading to cell cycle arrest. Paclitaxel

    ReplyDelete